A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Clinical trial NCT07205315 · RECRUITING

Trial details

NCT number: NCT07205315
Sponsor: Grit Biotechnology
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia (B-ALL)Chronic Lymphocytic Leukemia (CLL)B-cell Non-Hodgkin's Lymphoma (B-NHL)Autoimmune Hemolytic Anemia (AIHA)

Start date: 2025-09-26
Primary completion: 2027-11-30
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.